Gabapentin to Reduce Alcohol and Improve Viral Load Suppression

PHASE2RecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

November 20, 2023

Primary Completion Date

August 31, 2026

Study Completion Date

May 31, 2027

Conditions
HIVHeavy Drinking
Interventions
DRUG

Gabapentin

Dosing will be titrated up over 3 weeks, starting with a daily dose of 300mg (1 capsule/day) in week 1, followed by a daily dose of 900mg (3 capsules/day) in week 2, up to a target daily dose of 1800mg (6 capsules/day) in week 3. The target dose of 1800mg per day will be sustained from weeks 3 through day 4 of week 12. Then, dose will be tapered down to 900mg in days 5-7 of week 12, and medication will be discontinued at the end of week 12.

DRUG

Placebo

Participants randomized to this group will receive a placebo medication for 3 months and will be instructed to follow the same pill regimen as the intervention arm.

Trial Locations (1)

Unknown

RECRUITING

Mbarara Regional Referral Hospital (MRRH): Immune Suppression Syndrome HIV, Mbarara

Sponsors
All Listed Sponsors
collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

lead

Boston Medical Center

OTHER